logo

Apellis Pharmaceuticals, Inc. (APLS)



Trade APLS now with
  Date
  Headline
11/16/2020 7:11:02 AM Apellis: FDA Accepts & Grants Priority Review Designation For Pegcetacoplan NDA For Paroxysmal Nocturnal Hemoglobinuria
10/3/2020 12:49:48 PM Apellis Pharma Presents Results Of Post Hoc Analysis Of Phase 2 FILLY Study Of Intravitreal Pegcetacoplan (APL-2)
9/15/2020 7:28:56 AM Apellis Announces Submission Of NDA To FDA And EMA For Pegcetacoplan Marketing Applications For Patients With PNH
7/2/2020 8:09:24 AM Apellis Completes Enrollment In Phase 3 Study Of Pegcetacoplan
5/28/2020 7:03:36 AM Apellis Begins Phase 1/2 Study Of APL-9 In Patients With Severe COVID-19
4/6/2020 8:20:05 AM Apellis Adds Paul Fonteyne To Board
1/8/2020 10:37:40 PM Apellis Pharma Prices Public Offering Of 9.5 Mln Shares At $37.00/shr
1/7/2020 7:07:57 AM Apellis Pharma Says Pegcetacoplan Meets Primary Endpoint In The PEGASUS Study
9/18/2019 8:11:06 AM Apellis Pharma Publishes Phase 2 Study In Ophthalmology Highlights Efficacy And Safety Data Of Intravitreal APL-2
7/22/2019 7:13:40 AM Apellis Pharma Appoints Lucia Celona As Chief People Officer
6/15/2019 10:57:08 AM Apellis Pharma Presents Data From Ongoing APL-2 Phase 2 Study At 24th EHA Congress
3/7/2019 7:14:35 AM Apellis Pharma Prices Public Offering Of 6 Mln Shares $17/Shr
1/31/2019 9:03:49 AM Apellis Appoints Thomas Lackner As SVP, Head Of Europe
12/20/2018 7:12:13 AM Apellis Pharma Provides Update On Its Phase 3 Program For Patients With Geographic Atrophy
9/12/2018 7:36:00 AM Apellis Begins Phase 3 Clinical Program For APL-2 In Patients With Geographic Atrophy